Ladies and gentlemen, thank you for standing by. Hello, welcome to Ultragenyx Pharmaceutical Inc. 2026 Annual Meeting of Stockholders. All lines have been placed on mute to prevent any background noise. Thank you. I would now like to turn the conference over to our Chairman of the Board, Dan Welch. Please go ahead.
Thank you, operator. Good morning, ladies and gentlemen, and welcome to the 2026 Annual Meeting of Stockholders of Ultragenyx Pharmaceutical Inc. My name is Daniel G. Welch, and I serve as the Chairman of the Board. Other members of the Board are Dr. Deborah Dunsire, Matthew Fust, Dr. Emil Kakkis, Michael Narachi, Dr. Amrit Ray, Dr. Corsee Sanders, and Dr . Shehnaaz Suliman . I will be presiding over this meeting. At this time, I call the meeting to order. Emil Kakkis, our President and CEO, is present and will walk us through the rest of the meeting. Emil?
Thank you, Dan. Joining us today is Karah Parschauer, Executive Vice President and Chief Legal Officer in Corporate Affairs. Karah will act as secretary of the meeting and the inspector of elections. We're also joined today by Michael Formolo from our independent auditor, Ernst & Young LLP. During the question and answer period at the end of the meeting, Michael will be available to answer questions concerning Ernst & Young services to the company, including the audit of the company's financial statements.
As noted in the notice and proxy statement previously provided to stockholders, the record time for voting at this meeting was the close of business on March 23rd, 2026. A list of the registered stockholders on the record date is available for inspection during this meeting and can be found at the URL used to access this meeting.
Notice of this stockholder meeting was mailed on or about March 27, 2026 to all stockholders entitled to vote as of the record date. Broadridge has delivered an affidavit of distribution to show that notice of this meeting was given. The notice and affidavit will be incorporated into the minutes of this meeting. The secretary will now report on the shares present at this meeting.
Thank you, Emil. As of the record date, there were 98,317,221 shares of common stock outstanding and entitled to vote. As Inspector of Elections, I can also report that there are at least 84,786,388 shares of common stock represented at this meeting, or approximately 86% of all shares entitled to vote.
Thank you, Karah. Based on the percentage of total shares of the company held by holders of record now present at the meeting, a quorum is present. The meeting is now duly convened for the purposes of transacting business properly before it. Emil?
If you've already turned in your proxy card, you should not vote again unless you wish to revoke your proxy or change your vote. If you'd like to vote at today's annual meeting, you will have the opportunity to do so shortly. At this meeting, stockholders will vote on the four proposals described in the proxy statement. Proposal number one is a reelection of three directors as class one directors.
Proposal number two is the approval of our third amended and restated 2023 incentive plan. Proposal number three is the ratification of the selection of Ernst & Young LLP as Ultragenyx's independent registered public accounting firm for the fiscal year ending December 31st, 2026. Proposal number four is an advisory non-binding vote to approve the compensation of the company's named executive officers.
The board recommends you vote for each of the three director nominees in proposal number one and for proposals numbers two, three, and four. If you've not already voted by proxy, please mark the appropriate box on the screen, which will then be electronically submitted to the Inspector of Elections.
The polls are now open for each matter to be voted on. The polls are now officially closed. The final vote totals will be published in the current report on Form 8-K that we will file within four business days. The Inspector of Elections will now report the preliminary vote results.
Based on a preliminary tally of votes cast in person and by proxy, I declare that the director nominees named in the proxy statement have been elected to hold office until the 2029 Annual Meeting of Stockholders. The third amended and restated 2023 Incentive Plan has been approved. The selection of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, has been ratified, and the compensation of the company's named executive officers have been approved. Dan?
Thank you, Karah. There being no further business, this concludes the formal portion of this meeting, and the meeting is now adjourned. Emil?
Thank you, Dan. We'll now entertain appropriate questions from stockholders. Are there any questions? Since there are no questions, we wanna thank you for attending the 2026 Annual Meeting of Stockholders. Goodbye.
The meeting has now concluded. Thank you all for joining. You may now disconnect.